MYOMO, INC.
MYOAbout the company
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living.
Investment snapshot
Positive
2
BUY / PASS
Neutral / negative
1 / 13
NEUTRAL / FAIL
Median fair value
—
No comparable estimates
Models with upside
0 / 17
Positive margin of safety
Key risk
No clean pass — all 13 investors flag at least one valuation criterion
Framework analysis
| Verdict | Meaning |
|---|---|
| BUY | Positive purchase signal: the framework's buy requirements are met. |
| PASS | The company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state. |
| NEUTRAL | Neither a positive nor negative conclusion. It does not mean to hold an existing position. |
| FAIL | The company does not clear the framework's requirements. |
| Ranked | Ranked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL. |
Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.
| Metric | Graham Defensive Value | Buffett Quality Compounder | Lynch GARP | Greenblatt Magic Formula | Piotroski F-Score | Dreman Contrarian Value | Munger Quality Focus | Pabrai Dhandho Framework | Akre Three-Legged Stool | Marks Risk-Aware Value | Ackman Activist Value | Templeton Global Bargain Hunter | Sleep Scale Economies Shared | Asness Systematic Factors | Neff Low-P/E Total Return | Schloss Asset-Value Discipline | O'Shaughnessy Systematic Factor Composite |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verdict | FAIL | FAIL | FAIL | FAIL · Rank #2836 (Top 91.6%) | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | PASS | FAIL | PASS | FAIL | FAIL | FAIL | NEUTRAL |
| Score | |||||||||||||||||
| Analysis | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… |
| Intrinsic Value (annual) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Margin of Safety | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financial Basis | TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025 Latest source filing: 2026-11-09 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-09 Score computed: 2026-11-14 | Annual history · FY 2025 · Balance sheet at 2026-09-30 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30 Latest source filing: 2026-11-09 Score computed: 2026-11-14 | TTM ended 2026-09-30 Latest source filing: 2026-11-09 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-09 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01 Latest source filing: 2026-11-09 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 Latest source filing: 2026-11-09 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-03-09 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment · Balance sheet at 2026-09-30 Latest source filing: 2026-11-09 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-03-09 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01 Latest source filing: 2026-11-09 Score computed: 2026-11-14 | Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-09-30 Latest source filing: 2026-11-09 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-03-09 Score computed: 2026-11-14 | TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025 Latest source filing: 2026-11-09 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-09 Score computed: 2026-11-14 | Annual history · FY 2025 · Balance sheet at 2026-09-30 Latest source filing: 2026-11-09 Score computed: 2026-11-14 | TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-11-09 Score computed: 2026-11-14 |
Where It Passes
Where It Falls Short
- Valuation0% pass✓ 1✗ 27▾
No clean pass — all 13 investors flag at least one valuation criterion
Price / 3-yr avg EPS✗Graham<= 15xPrice-to-Book Ratio4.2x✗Graham<= 1.5xP/E x P/B✗Graham<= 22.5Basic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)EBIT / Enterprise Value-24.7%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-24.7%, ROC=-531.5%✗GreenblattBoth EY > 10% and ROC > 25%Price / EPS✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)Price / (CFO / Shares)N/A (negative CFPS)✗Dreman< 8xPrice / Book Value per Share4.2x✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)Valuation Reasonableness✗MungerP/E < 25 or Owner Earnings Yield > 5%P/E or FCF YieldFCF Yield=-33.0%✗PabraiP/E < 15 or FCF Yield > 10%P/B or P/E vs. Historical AverageP/B=4.2x✗MarksP/E < 15 or P/B < 2.0Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePrice / FCF per ShareN/A (negative FCF)✗Ackman<= 25Price vs. Trailing Low182% of trailing low ($0.68)✗Templeton<= 120% of trailing low (certified split-adjusted live window)Net income / market capitalization-30.57%; #4811/6340 (top 75.9%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionPositive book equity / market capitalization+0.0558; #4975/6449 (top 77.1%)✗AsnessTop 30% of eligible cross-sectionPrice / Diluted EPS✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)(EPS CAGR % + Dividend Yield %) / P/E✗Neff> 0.7 (Neff's published traditional edge)Price / Tangible Book Value per Share4.15x✗SchlossP/TBV <= 1.00x (app cutoff)Book Value per Share Change✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)Revenue / market capitalization+0.9225; #1858/5247 (top 35.4%)✗OshaughnessyTop 10% of eligible cross-section(Operating cash flow - capex) / market capitalization-32.95%; #3699/4519 (top 81.9%)✗OshaughnessyTop 10% of eligible cross-sectionTrailing six-month price return through the evaluation date+78.26%; #441/6202 (top 7.1%)✓OshaughnessyTop 10% of eligible cross-section - Cash Flow0% pass✓ 1✗ 11▾
No clean pass — all 10 investors flag at least one cash flow criterion
Free Cash Flow Proxy✗BuffettPositive and growingFCF Positive and Growing$-16.3M✗LynchPositive and growingOperating Cash Flow$-14.5M✗PiotroskiCFO > 0(CFO / Total Assets) vs ROACFO/Assets=-37.56%, ROA=-40.31%✓PiotroskiCFO/Assets > ROAPrice / (CFO / Shares)N/A (negative CFPS)✗Dreman< 8xP/E or FCF YieldFCF Yield=-33.0%✗PabraiP/E < 15 or FCF Yield > 10%FCF Positive0/10 years FCF positive✗MarksPositive FCF in majority of recent years(OCF - CapEx) / Market Cap-34.3%✗Ackman>= 4%Price / FCF per ShareN/A (negative FCF)✗Ackman<= 25Positive Operating Cash Flow frequency0/10 years positive✗SleepPositive OCF in >= 70% of available yearsOperating Cash Flow - Capital Expenditures$-16.3M✗Neff> $0 (app proxy for a strong fundamental case)(Operating cash flow - capex) / market capitalization-32.95%; #3699/4519 (top 81.9%)✗OshaughnessyTop 10% of eligible cross-section - Profitability6% pass✓ 5✗ 30▾
15 of 16 flag MYO's profitability — Graham, Buffett, Lynch +12 more
Positive EPS (10 years)0/11 years positive✗GrahamPositive EPS every year for 10 yearsEPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)✗Graham>= 33% growthNet Income Positive (10+ years)0/11 years positive✗BuffettPositive every year for 10+ yearsROE (up to 5-year arithmetic mean)-97.6%✗Buffett> 15% arithmetic mean (app rule)Operating Margin (10-yr trend)-35.2% (latest)✓BuffettStable or rising over 10 yearsFree Cash Flow Proxy✗BuffettPositive and growingEarnings Variance (10-yr CoV)N/A (negative mean EPS)✗BuffettCoV < 0.3Retained Earnings Effectiveness✗Buffett$1 retained -> > $1 market value createdBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passROE-548.1%✗Lynch> 15%EBIT / Enterprise Value-24.7%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-24.7%, ROC=-531.5%✗GreenblattBoth EY > 10% and ROC > 25%Net Income / Total Assets-40.31%✗PiotroskiROA > 0ROA Change YoY-14.64% -> -40.31% (delta: -25.67%)✗PiotroskiCurrent ROA > Prior ROA(CFO / Total Assets) vs ROACFO/Assets=-37.56%, ROA=-40.31%✓PiotroskiCFO/Assets > ROAGross Margin Change YoY71.2% -> 65.7%✗PiotroskiImproved YoYPre-Tax Income / Revenue-32.2%✗Dreman>= 8%Net Income / Shareholders' Equity-548.1%✗Dreman> 12%Margin of SafetyP/B=4.2x✗PabraiP/B < 1.5 or P/E < 15Return on Equity-84.1% (3-yr avg)✗AkreROE > 20% (3-year avg)Discount to Intrinsic ValueN/A (negative normalized EPS)✗Marks>= 20% below intrinsic valuePositive Net Income Frequency0/10 years positive✗MarksPositive net income in >= 7 of last 10 yearsOperating Income / Revenue-21.8%✗Ackman>= 15%Net Income / Shareholders Equity-548.1%✗Ackman>= 15%5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Operating Margin Trend-42.8% (2023) -> -35.2% (2025)✓TempletonNon-negative operating-margin trend over 3 yearsRevenue growth vs. gross and operating margin trendgross margin 68.5% -> 65.7%, operating margin -42.8% -> -35.2%✓SleepRevenue rising; gross margin flat or falling; operating margin holdingNet income / market capitalization-30.57%; #4811/6340 (top 75.9%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionGross profit / total assets+94.42%; #161/3702 (top 4.3%)✓AsnessTop 30% of eligible cross-sectionNet income / positive book equity-548.13%; #5086/5226 (top 97.3%)✗AsnessTop 30% of eligible cross-sectionNegative 5-year standard deviation of ROA-0.2966; #4596/5884 (top 78.1%)✗AsnessTop 30% of eligible cross-section3-5 Year Diluted EPS CAGR✗Neff7%-20% annualizedPositive Diluted-EPS Years0/10 years positive✗Schloss>= 70% positive over 5-10 observed years (app rule) - Verdicts13% pass✓ 2✗ 14▾
Split decision: 13 FAIL · 2 PASS · 1 NEUTRAL
Overall verdict✗GrahamFAIL (0/9)✗BuffettFAIL (1/9)✗LynchFAIL (1/7)✗GreenblattRank #2836✗PiotroskiFAIL (F-Score 3)✗DremanFAIL (2/11)✗MungerFAIL (0/4)✗PabraiFAIL (0/3)✗AkreFAIL (1/6)✗MarksFAIL (0/5)✓AckmanPASS (4/9)✗TempletonFAIL (3/8)✓SleepPASS (3/6)✗AsnessFAIL (Rank #1811/2370 (Top 76.4%))✗NeffFAIL (1/6)✗SchlossFAIL (2/7)•OshaughnessyNEUTRAL (Not ranked) - Growth25% pass✓ 5✗ 8▾
6 of 8 flag MYO's growth — Graham, Lynch, Dreman +3 more
EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)✗Graham>= 33% growthBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passInventory Growth vs Revenue GrowthInv: -15.1% vs Rev: 9.3%✓LynchInventory growth < Revenue growthEPS Growth Direction$-4.13 (2016) -> $-0.37 (2025)✗DremanPositive over recent yearsEPS CAGR✗Dreman> 5% annualizedPositive Net Income Frequency0/10 years positive✗MarksPositive net income in >= 7 of last 10 years3yr Median Revenue Growth25.7%✓Ackman>= 5%Positive EPS Growth Frequency4/5 years with positive EPS growth✓AckmanPositive EPS growth in >= 3 of last 5 years5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Revenue growth vs. gross and operating margin trendgross margin 68.5% -> 65.7%, operating margin -42.8% -> -35.2%✓SleepRevenue rising; gross margin flat or falling; operating margin holding5-year Revenue CAGR40.1%✓SleepCAGR > 7%3-5 Year Diluted EPS CAGR✗Neff7%-20% annualized - Efficiency25% pass✓ 3✗ 8▾
6 of 8 flag MYO's efficiency — Graham, Buffett, Greenblatt +3 more
Current Ratio1.92✗Graham>= 2.0ROIC (3-5 yr avg)-584.6%✗Buffett> 10%ROIC - WACC-594.6%✗BuffettPositive (WACC = 10%)EBIT / (NWC + Net Fixed Assets)-531.5%✗Greenblatt> 25%Current Ratio Change YoY3.22 -> 3.30✓PiotroskiIncreased YoYRevenue / Total Assets Change YoY0.77x -> 1.06x✓PiotroskiImproved YoYCurrent Assets / Current Liabilities1.92✓Dreman> 1.5Return on Invested Capital-166.4%✗Munger> 15%ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=-19.8%; FY2025: ROIC=-50.3%✗AkreLatest 3 consecutive FYs: ROIC > 15% in eachReinvestment Rate x ROICN/A (non-positive net income)✗AkreReinvestment Rate * ROIC > 10%ROIC (5-year)0/2 years above 12% (latest -50.3%)✗SleepROIC > 12% in a majority of years - Debt & Leverage33% pass✓ 6✗ 9▾
8 of 12 flag MYO's debt & leverage — Graham, Buffett, Lynch +5 more
LT Debt vs Net Current AssetsLT Debt $11.7M vs NCA $11.2M✗GrahamLT Debt <= Net Current AssetsDebt/Equity & Interest CoverageD/E: 0.98, IC: -128.7x✗BuffettD/E < 0.5 AND Interest Coverage > 5xTotal Debt / Equity0.71✗Lynch< 0.33Cash - Long-term Debt$-0.6M✗LynchPositive preferredLT Debt / Total Assets Change0.00% -> 29.05%✗PiotroskiDecreased YoYCurrent Assets / Current Liabilities1.92✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)Total Debt / Shareholders' Equity0.71✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00xDebt Levels0.71✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3Interest Coverage & Debt/EBITDAIC=-128.7x, D/EBITDA=N/A (D&A unavailable)✗MarksInterest Coverage > 3x; Debt/EBITDA < 4xTotal Debt / Shareholders Equity0.71✓Ackman<= 1.0Negative debt-to-equity (higher means less debt)-0.7105; #2863/4210 (top 68.0%)✗AsnessTop 30% of eligible cross-section
Business & financials
Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.
Company Profile
Financial Snapshot
Shareholder Return
Fiscal 2025
Issued 12.0% of shares last year, 41.9% issued over two.
- Buybacks
- —
- Dividends
- —
Company Financials
Latest TTM and quarters alongside annual years
TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.
The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.
| Metric | TTM · 2026-09-30 2025-10-01 – 2026-09-30 Sources · derived quarter valuesDerived from cumulative filings: revenue, net income, operating income, gross profit, ebit, pre tax income, operating cash flow, depreciation amortization, capex. | Q3 FY 2026 2026-07-01 – 2026-09-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, depreciation amortization, capex. | Q2 FY 2026 2026-04-01 – 2026-06-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, depreciation amortization, capex. | Q1 FY 2026 2026-01-01 – 2026-03-31 Sources | FY 2025Sources
| FY 2024Sources
| FY 2023Sources
| FY 2022Sources
| FY 2021Sources
|
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $49.3Mcurrent | -- | -- | -- | $32.3Mest. | $207.3Mest. | $90.4Mest. | $3.7Mest. | $49.5Mest. |
| Revenue | $45.5M↑9% | $12.3M↑22% | $11.7M↑21% | $10.1M↑3% | $40.9M↑26% | $32.6M↑69% | $19.2M↓98% | $1.0B↑7117% | $13.9M |
| Operating Income | -$9.9M↑17% | -$1.7M↑51% | -$2.3M↑51% | -$3.2M↑10% | -$14.4M↓132% | -$6.2M↑25% | -$8.2M↑23% | -$10.7M↓4% | -$10.3M |
| Net Income | -$15.1M↓25% | -$4.2M↓16% | -$4.0M↑13% | -$3.0M↑13% | -$15.6M↓152% | -$6.2M↑24% | -$8.1M↑24% | -$10.7M↓3% | -$10.4M |
| EPS (Diluted) | -- | $-0.10↓11% | $-0.09↑18% | $-0.07↑12% | $-0.37↓131% | $-0.16↑43% | $-0.28↑82% | $-1.52↑20% | $-1.89 |
| Gross Margin | 70.1%↑5% | 71.3%↑12% | 72.1%↑15% | 68.2%↑2% | 65.7%↓8% | 71.2%↑4% | 68.5%↑6582% | 1.0%↓99% | 74.4% |
| Operating Margin | -21.8%↑24% | -14.0%↑60% | -19.3%↑59% | -31.2%↑13% | -35.2%↓85% | -19.1%↑55% | -42.8%↓3909% | -1.1%↑99% | -74.1% |
| ROE | -548.1%↓567% | — | — | — | -136.6%↓446% | -25.0%↑72% | -90.6%↑46% | -168.6%↓150% | -67.3% |
| Total Debt | $2.0M↓19% | $2.0M↓19% | $611.4K↓54% | $10.9M | $11.2M | $0 | -- | -- | -- |
| Shareholders' Equity | $2.8M↓81% | $2.8M↓81% | $5.8M↓67% | $9.0M↓58% | $11.4M↓54% | $24.7M↑175% | $9.0M↑41% | $6.4M↓59% | $15.4M |
| Current Ratio | 1.92↓23% | 1.92↓23% | 2.31↓3% | 2.73↑3% | 3.30↑2% | 3.22↑29% | 2.49↓3% | 2.56↓43% | 4.46 |
| Debt / Equity | 0.71↑330% | 0.71↑330% | 0.10↑39% | 1.21 | 0.98 | 0.00 | — | — | — |
| Operating Cash Flow | -$6.6M↑34% | -$1.3M↑29% | -$1.9M↑78% | -$2.2M↑18% | -$14.5M↓341% | -$3.3M↑47% | -$6.2M↑40% | -$10.2M↓7% | -$9.5M |
| Free Cash Flow | -- | -$1.4M↑53% | -$2.0M↑80% | -$2.5M↑25% | -$16.3M↓250% | -$4.7M↑26% | -$6.3M↑39% | -$10.3M↓5% | -$9.9M |
Score history
Historical Score Timeline
Industry peers
Industry Peers
Similar companies in Medical Equipment
MYO vs Peers — Financial Grading
| Company | Market Cap | Price | Revenue | Net Income | ROE | D/E | Op. Margin | Curr. Ratio | Graham | Buffett | Lynch | Greenblatt | Piotroski | Dreman |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALCON INCALC | $35.6B | $74.12 | $10.4B | $980.0M | 4.4% | 0.21 | 13.1% | 2.12 | 2/9 | 1/9 | 3/7 | 0/3 | F-Score 6 | 4/11 |
| KONINKLIJKE PHILIPS NVPHG | $29.7B | $30.34 | $21.0B | $1.1B | 8.2% | 0.64 | 8.0% | 1.32 | 1/9 | 1/9 | 1/7 | 0/3 | F-Score 5 | 3/11 |
| WEST PHARMACEUTICAL SERVICES INCWST | $29.0B | $416.42 | $3.1B | $493.7M | 15.5% | 0.06 | 19.0% | 3.02 | 4/9 | 6/9 | 6/7 | 1/3 | F-Score 7 | 5/11 |
| SMITH & NEPHEW PLCSNN | $13.1B | $31.28 | $6.2B | $625.0M | 11.8% | 0.59 | 12.9% | 2.57 | 2/9 | 0/9 | 1/7 | 0/3 | F-Score 6 | 4/11 |
| MSA Safety IncMSA | $6.7B | $174.17 | $1.9B | $278.9M | 20.4% | 0.42 | 19.8% | 3.01 | 5/9 | 5/9 | 4/7 | 1/3 | F-Score 5 | 7/11 |
| STAAR SURGICAL COSTAA | $1.3B | $26.39 | $239.4M | $80.4M | -23.4% | — | -38.3% | 4.55 | 2/9 | 2/9 | 2/7 | 0/3 | F-Score 3 | 3/11 |
| ARTIVION, INC.AORT | $931.9M | $19.10 | $441.3M | $9.8M | 2.2% | 0.48 | 7.6% | 3.53 | 2/9 | 0/9 | 0/7 | 0/3 | F-Score 7 | 1/11 |
| InMode Ltd.INMD | $763.6M | $13.27 | $370.5M | $93.8M | 13.7% | — | 23.0% | 9.88 | 5/9 | 3/9 | 0/7 | 3/3 | F-Score 4 | 4/11 |